IP Library › Granted Patent US 10,016,500
Granted Patent B2
US 10,016,500 · App. 14/640,002 · Granted Jul 10, 2018

Poloxamer-based pharmaceutical compositions for treating wounds

Inventor: Daniel Banov (Sugar Land, TX)
Assignee: Professional Compounding Centers of America
A61K47/10A61K9/006A61K9/1617A61K31/496
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,500
App. No.
14/640,002
Granted
Jul 10, 2018
Kind
B2
Abstract

Compositions and methods for treating bacterial, fungal, and yeast infections in wounds are disclosed. The disclosed poloxamer-based pharmaceutical composition includes a micronized poloxamer composition base combined with one or more suitable active pharmaceutical ingredients (APIs), such as, antibacterial or antifungal, thereby resulting in a synergistic effect for the APIs. The micronized poloxamer composition within poloxamer-based pharmaceutical composition includes poloxamer 407 and poloxamer 188. Poloxamer-based pharmaceutical composition exhibits a particle size average of about 50 μm, which enhance APIs solubility. Additionally, poloxamer-based pharmaceutical composition can be delivered in a plurality of dosage forms, such as, powders, sprays, ointments, pastes, creams, lotions, solutions, and patches, among others.

Claims (8)

1. A powdered pharmaceutical composition for wound treatment, consisting of a pharmaceutically effective amount of itraconazole particles, poloxamer 407 and poloxamer 188 wherein each of the poloxamer 407 and poloxamer 188 has a median particle size in the range of about 30 μm to about 70 μm.

2. The pharmaceutical composition of claim 1 , wherein the poloxamer 407 is present in a range of about 1% to about 50% by weight.

3. The pharmaceutical composition of claim 1 , wherein the poloxamer 407 is present at about 20% by weight.

4. The pharmaceutical composition of claim 1 , wherein the poloxamer 188 is present in a range of about 1% to about 50% by weight.

5. The pharmaceutical composition of claim 1 , wherein the poloxamer 188 is present at about 20% by weight.

6. The pharmaceutical composition of claim 1 , wherein each of the poloxamer 407 and poloxamer 188 has a median particle size of about 50 μm.

7. The pharmaceutical composition of claim 1 , wherein the itraconazole particles are mixed with the poloxamer 407 and poloxamer 188 by applying a low-frequency acoustic field.

8. The pharmaceutical composition of claim 1 , wherein the poloxamer 407 and poloxamer 188 are produced using a microprilling process.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2016
From: BANOV, DANIEL
To: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA)
Reel/Frame 038216/0593 →
Continuity (2)
Provisional Application 61948180 · Mar 5, 2014
Related Publication 20150250876A1 · Sep 10, 2015